| Outcome Measures: |
Primary: Number of Participants With Adverse Events, From the first dose of study drug in the parent study (20120331) through 30 days after the last dose in the extension study; actual median duration of treatment was 439 days. | Secondary: Percent Change From Baseline in Parathyroid Hormone, Baseline was defined as the average of 3 predialysis results obtained within 3 weeks before the first dose of etelcalcetide in the parent study (20120331). The week numbering for this study continued from the parent study 20120331 hence the first measurement for all parameters in the extension study started at week 13., Baseline (of the parent study 20120331) and Weeks 13, 26 and 52|Percent Change From Baseline in Serum Corrected Calcium, Baseline was defined as the average of 3 predialysis results obtained within 3 weeks before the first dose of study drug in the parent study (20120331). The week numbering for this study continued from the parent study 20120331; the first measurement for all parameters in the extension study started at week 13., Baseline and Weeks 13, 26 and 52|Percent Change From Baseline in Serum Phosphorus, Baseline was defined as the average of 3 predialysis results obtained within 3 weeks before the first dose of study drug in the parent study (20120331). The week numbering for this study continued from the parent study 20120331; the first measurement for all parameters in the extension study started at week 13., Baseline and Weeks 13, 26 and 52
|
